

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Anatara Lifesciences Limited
ABN	41 145 239 872

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	David Brookes
Date of last notice	14 December 2022

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct & Indirect
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	Indirect – David & Elisabeth Brookes atf Dr DL Brookes Personal Superfund & David & Elisabeth Brookes atf Dahlbrook Family Trust
Date of change	Ordinary Shares: 16 December 2022 & Options: 19 December 2022
No. of securities held prior to change	Direct: 900,000 at \$0.225 ea; vesting 450,000 16 November 2022 & 450,000 16 November 2023; expire 14 November 2025 Indirect – David & Elisabeth Brookes atf Dr DL Brookes Personal Superfund 450,000 Ordinary Shares
Class	Ordinary Shares & Options exercisable at \$0.07 ea expiring 11 December 2025

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Number acquired	<p>Direct – David Brookes 350,000 Ordinary Shares with attaching 175,000 Options</p> <p>Indirect – David & Elisabeth Brookes atf Dr DL Brookes Personal Superfund 792,858 Ordinary Shares with attaching 396,429 Options</p> <p>& David & Elisabeth Brookes atf Dahlbrook Family Trust 571,428 Ordinary Shares with attaching 285,714 Options</p> <p>All purchased under the Tranche 2 Placement approved by Shareholders at the General Meeting held on 12 December 2022</p>
Number disposed	Nil
Value/Consideration <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	\$60,000
No. of securities held after change	<p>Direct:</p> <p>Ordinary Shares: 350,000 Ordinary Shares</p> <p>Options: 900,000 at \$0.225 ea; vesting 450,000 16 November 2022 & 450,000 16 November 2023 expire 14 November 2025; and 175,000 Options exercisable at \$0.07 ea expiring 11 December 2025</p> <p>Indirect – David & Elisabeth Brookes atf Dr DL Brookes Personal Superfund 1,242,858 Ordinary Shares and 396,429 Options exercisable at \$0.07 ea expiring 11 December 2025</p> <p>David & Elisabeth Brookes atf Dahlbrook Family Trust 571,428 Ordinary Shares and 285,714 Options exercisable at \$0.07 ea expiring 11 December 2025</p>
Nature of change <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small>	Shares with attaching Options purchased following Shareholder approval at the General Meeting held on 12 December 2022

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	Nil
Nature of interest	

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	
Interest acquired	
Interest disposed	
Value/Consideration <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	
Interest after change	

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	N/A
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

⁺ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Anatara Lifesciences Limited
ABN	41 145 239 872

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Jane Ryan
Date of last notice	14 December 2022

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	N/A
Date of change	Ordinary Shares: 16 December 2022 & Options: 19 December 2022
No. of securities held prior to change	Direct – 183,078 Ordinary Shares; 450,000 Options at \$0.225 ea; vesting 225,000 16 November 2022 & 225,000 16 November 2023; expire 14 November 2025
Class	Ordinary Shares & Options exercisable at \$0.07 ea expiring 11 December 2025
Number acquired	Indirect: Jane Ryan Holding Pty Ltd atf Jane Ryan Superfund 142,858 Ordinary Shares purchased under the Tranche 2 Placement approved by Shareholders at the General Meeting held on 12 December 2022 & attaching 71,429 Options

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Number disposed	Nil
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	\$5,000
No. of securities held after change	<p>Direct – 183,078 Ordinary Shares; 450,000 Options at \$0.225 ea and vesting 225,000 16 November 2022 & 225,000 16 November 2023, expire 14 November 2025</p> <p>Indirect: Jane Ryan Holding Pty Ltd atf Jane Ryan Superfund 142,858 Ordinary Shares and 71,429 Options exercisable at \$0.07 ea expiring 11 December 2025</p>
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Shares with attaching Options purchased following Shareholder approval at the General Meeting held on 12 December 2022

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	Nil
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	
Interest disposed	
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	

Part 3 – +Closed period

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

Were the interests in the securities or contracts detailed above traded during a ⁺ closed period where prior written clearance was required?	N/A
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

⁺ See chapter 19 for defined terms.